BriaCell (BCTX) Therapeutics announces that the Data Safety Monitoring Board has completed its first review of safety events in patients enrolled in BriaCell’s pivotal randomized Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor combination regimen. The DSMB issued a statement recommending continuation of the study in metastatic breast cancer patients. BriaCell’s pivotal Phase 3 study is currently being conducted under Fast Track Designation with the Food and Drug Administration.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BCTX:
- BriaCell Highlights Promising Breast Cancer Trial Results
- BriaCell to highlight OS, clinical benefit data of Bria-IMT in MBC patients
- BriaCell director Marc Lustig resigns
- BriaCell Advances Cancer Treatment with New Trial
- BriaCell announces first patient dosed with Bria-OTS in Phase 1/2 study
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
